Drug Trial Radar · NCT04269902
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
247
Planned (sponsor's estimate)
Start
Mar 2, 2021
Primary completion
Oct 1, 2028
Study completion Oct 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Feb 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Conditions
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
Interventions
Biospecimen CollectionProcedure
Undergo collection of blood samples
Bone Marrow AspirationProcedure
Undergo bone marrow aspiration
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Computed TomographyProcedure
Undergo CT
ObinutuzumabBiological
Given IV
Questionnaire AdministrationOther
Ancillary studies
VenetoclaxDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: From the day of registration on study until death from any cause with observations censored on the day of last contact for participants not known to have died, assessed up to 10 years
- Functional Assessment of Cancer Therapy (FACT)-Leukemia total scoreTime frame: At 2 years
Locations
633 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama · Active not recruiting
Anchorage Associates in Radiation Medicine
Anchorage, Alaska · Suspended
Anchorage Radiation Therapy Center
Anchorage, Alaska · Suspended
Alaska Breast Care and Surgery LLC
Anchorage, Alaska · Suspended
Alaska Oncology and Hematology LLC
Anchorage, Alaska · Suspended
Alaska Women's Cancer Care
Anchorage, Alaska · Suspended
Anchorage Oncology Centre
Anchorage, Alaska · Suspended
Katmai Oncology Group
Anchorage, Alaska · Suspended
Providence Alaska Medical Center
Anchorage, Alaska · Suspended
Fairbanks Memorial Hospital
Fairbanks, Alaska · Suspended
Cancer Center at Saint Joseph's
Phoenix, Arizona · Active not recruiting
Banner University Medical Center - Tucson
Tucson, Arizona · Recruiting
University of Arizona Cancer Center-North Campus
Tucson, Arizona · Recruiting
Mercy Hospital Fort Smith
Fort Smith, Arkansas · Suspended
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas · Suspended
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro, Arkansas · Recruiting
Kaiser Permanente-Anaheim
Anaheim, California · Recruiting
Mission Hope Medical Oncology - Arroyo Grande
Arroyo Grande, California · Active not recruiting
Kaiser Permanente-Baldwin Park
Baldwin Park, California · Recruiting
Kaiser Permanente-Bellflower
Bellflower, California · Recruiting
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California · Suspended
Marshall Cancer Center
Cameron Park, California · Recruiting
Mercy Cancer Center - Carmichael
Carmichael, California · Active not recruiting
Mercy San Juan Medical Center
Carmichael, California · Active not recruiting
Enloe Medical Center
Chico, California · Recruiting
UC Irvine Health Cancer Center-Newport
Costa Mesa, California · Recruiting
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
Mercy Cancer Center - Elk Grove
Elk Grove, California · Active not recruiting
Kaiser Permanente-Fontana
Fontana, California · Recruiting
Kaiser Permanente South Bay
Harbor City, California · Recruiting
City of Hope Seacliff
Huntington Beach, California · Recruiting
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California · Recruiting
City of Hope at Irvine Lennar
Irvine, California · Recruiting
Kaiser Permanente-Irvine
Irvine, California · Recruiting
UCI Health Laguna Hills
Laguna Hills, California · Recruiting
City of Hope Antelope Valley
Lancaster, California · Recruiting
City of Hope at Long Beach Elm
Long Beach, California · Recruiting
Tibor Rubin VA Medical Center
Long Beach, California · Active not recruiting
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California · Recruiting
Kaiser Permanente West Los Angeles
Los Angeles, California · Recruiting
Showing 40 of 633 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.